Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias

International Journal of Cancer

Volumn 120, Issue 2, 2007, Pages 297-302

  Suspitsin, Evgeny N ^a   Sokolenko, Anna P ^a   Togo, Alexandr V ^a   Lazareva, Yulia R ^a   Turkevich, Elena A ^a   Matsko, Dmitry E ^a   Henrich, Kai Oliver ^b   Borresen Dale, Anne Lise ^c   Schwab, Manfred ^b   Cornelisse, Cees J ^d   Imyanitov, Evgeny N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Bilateral breast cancer; Oncogene amplifications; Real time PCR

Indexed keywords

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GENETICS; CANCER SURVIVAL; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; MICRODISSECTION; ONCOGENE; ONCOGENE C MYC; ONCOGENE CCND1; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CYCLIN D1; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, MYC; HUMANS; MIDDLE AGED; ONCOGENES; POLYMERASE CHAIN REACTION;

EID: 33845614956     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22265     Document Type: Article

References (24)

1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-61.
2. Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer. Cancer Lett 2003;191:1-7.
3. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 2005;6:377-82.
4. Hemminki K, Granstrom C. Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined? Breast Cancer Res 2002;4:R7.
5. Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, Di Fronzo G. Is steroid receptor protile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 1998;34:825-30.
6. Kollias J, Pinder SE, Denley HE, Ellis IO, Wencyk P, Bell JA, Elston CW, Blamey RW. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat 2004;85:255-61.
7. Imyanitov EN, Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ESh, Belogubova EV, Pozharisski KM, Turkevich EA, Rodriquez C, Cornelisse CJ, Hanson KP, Theillet C. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer 2002;100:557-64.
8. Imyanitov EN, Hanson KP. Mechanisms of breast cancer. Drug Discov Today Dis Mech 2004;1:235-45.
9. Imyanitov EN, Suspitsin EN, Buslov KG, Kuligina ESh, Belogubova EV, Togo AV, Hanson KP. Isolation of nucleic acids from paraffin-embedded archival tissues and other difficult sources. In: Kieleczawa J, ed. The DNA book: protocols and procedures for the modern molecular biology laboratory. Jones and Bartlett. Sudbury: MA, 2006. 85-97.
10. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-18.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
12. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin Chem 2002;48:1178-85.
13. Loginova AN, Pospekhova NI, Lyubchenko LN, Budilov AV, Zakhar'ev VM, Gar'kavtseva RF, Ginter EK, Karpukhin AV. Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families. Bull Exp Biol Med 2003;136:276-8.
14. Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina ESh, Sokolenko AP, Matsko DE, Turkevich EA, Lazareva YR, Chagunava OL, Bit-Sava EM, et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer 2005;114:585-9.
15. Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina Yu M, Rozanov ME, Mitiushkina NV, Togo AV, Matsko DE, Voskresenskiy DA, Chagunava OL, Devilee P, et al. CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat. in press.
16. Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, Kuligina ESh, Ulibina YuM, Rozanov ME, Suspitsin EN, Matsko DE, Chagunava OL, et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 2006;42:1380-4.
17. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5:943-55.
18. Kuo WH, Yen AM, Lee PH, Hou MF, Chen SC, Chen KM, Chen TH, Chang KJ. Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat 2006;99:221-8.
19. Kuligina ESh, Grigoriev MYu, Suspitsin EN, Buslov KG, Zaitseva OA, Yatsuk OS, Lazareva YuR, Togo AV, Imyanitov EN. Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies. J Cancer Res Clin Oncol. in press.
20. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23.
21. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-95.
22. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001;61 (Suppl 2):67-72.
23. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
24. Jirstrom K, Stendahl M, Ryden L, Kronhlad A, Bendahl PO, Stal O, Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005;65: 8009-16.